BeyondSpring is trading 5.5% up at $0.75, with biotech-sector momentum a stronger explanation for the move after no fresh company-specific announcement was identified on August 25, 2026.
- The latest company release, dated August 14, reported second-quarter results and positive long-term plinabulin clinical data, but does not directly explain the current move.
- XBI advanced 2.06% during regular trading as biotechnology moved higher alongside broader equities.